Combined Effect of Transfusion and Blood Groups on the Survival of Patients With Breast Cancer. A Clinical Study of 901 Patients †

Abstract

Previous reports by the authors and by others have shown that trans fusion adversely affects the survival of cancer patients. To delineate fur ther the mechanism of action of blood transfusion on biological behavior of cancer, the authors studied the role of the major blood groups ABO in 901 patients who had all undergone radi cal surgery for operable primary breast cancer and among whom 294 had received at least one unit of whole blood perioperatively.

Multivariate analysis using Cox's regression models on life tables was used. It was found that the adverse effect of transfusion on survival was a blood group-related phenomenon manifesting its action in patients with blood groups A and B (P = 0.0006 and P = 0.006 respectively). The most im pressive effect of transfusion was seen in patients whose age was be tween forty-one and fifty (51.9% ten- year actuarial survival in 47 transfused patients compared with 73.9% in 70 nontransfused ones).

A hypothesis is presented suggest ing that transfusion exerts its effect on the hemostatic system, promoting clotting in group A and B patients and fibrinolysis in group O and AB patients, and thus affects metastatic cascade, with results that have been presented in this series.

Get full access to this article

View all access options for this article.

References

Opelz G. , Sengar DP , Mickey MR , et al: Effect of blood transfusion on subsequent kidney transplants . Transplantat Proc 5:253-259, 1973.

Salsali M. , Bufalino R. , Morabito A. : Breast cancer survival and transfusion: A clinical study of 900 patients . In press.

Jinck H. , Westerholm B. , Vessey MP , et al: Venous thromboembolic disease and ABO blood type. Lancet i:539-542, 1969.

Cox DR : Regression models on life table (with discussion). J Roy Stat Soc B 34:178-202, 1972.

Marubini E. , Morabito A. , Valscchi MG : Prognostic factors and risk groups: Some results given by using an alogrithm suitable for censored survival data. Stat Med 2:295-303, 1983.

Morabito A. , Marubini E. : TABSUR: A program featured to aid analysis in cancer research. Acts de le journée de Travail: Analyse de Donnée Napoli, June, 1980 . INRIA, Lechesenay, pp 393-408.

Freiman JA , Chalmers TC , Smith H. , et al: The importance of beta, the Type II error and sample size in the design and interpreation of the randomized control trial. N Engl J Med 299:690-694, 1978.

Voogt PJ , van de Velde CJH , Brand A. , et al: Perioperative blood transfusion and cancer prognosis: Different effects of blood transfusion on prognosis of colon and breast cancer patients . Cancer 59:836-843, 1987.

Foster RS , Foster JC , Costanza MC : Blood transfusion and survival after surgery for breast cancer. Arch Surg 119:1138-1140, 1984 .

10.

Munzarová M. , Kavorik J. , Hlávkova J. , et al: Course of breast cancer disease and ABO blood group. Biomed Pharmacother 39:486-489, 1985.

11.

Burrows L. , Tartter PI : Effect of blood transfusion on colonic malignancy recurrence rate . Lancet 2:662, 1982.

12.

Tartter PI , Burrows L. , Kirscner P. : Perioperative blood transfusion adversely affects prognosis after resection of stage I (subset NO) non-oat cell lung cancer. J Thorac Cardiovasc Surg 88:659-662, 1984.

13.

Rosenberg SA , Seipp CA , White DE , et al: Perioperative blood transfusions are associated with increased rates of recurrence and decreased survival in patients with high-grade soft-tissue sarcomas of the extremities . J Clin Oncol 3:698-708, 1985.

14.

Blumberg N. , Heal J. , Murphy P. , et al: Association between transfusion of whole blood and recurrence of cancer. Br Med J 293:530-533, 1986.

15.

Lehnard V. , Massen G. , Gross-Wilde HH , et al: Effect of blood transfusion on immunoregulatory mononuclear cells in prospective transplant recipients. Transplant Proc 15:1011-1015, 1983.

16.

Smith MD , William JD , Coles GA , et al: The effect of blood transfusion on T-suppressor cells in renal dialysis patients. Transplant Proc 13:181-183, 1981.

17.

Fehrman I. , Ringdén O. : Reduced immunologic responsiveness in multitransfused anemic nonuremic patients . Transplant Proc 14:341-343, 1982.

18.

McLoughlin RG , Wu AV , Saporoschetz I. , et al: Correlation between anergy and circulating immunosuppressive factor following major surgical trauma. Ann Surg 190:297-303, 1979.

19.

Dintenfass L. , Stewart JH , Milton GW , et al: Influence of ABO blood groups and fibrinogen on thrombus formation and aggregation of red cells in cardiovascular and malignant disease. Biorheology 10:585-594, 1973.

20.

Fidler IJ : Tumor heterogeneity and biology of cancer invasion and metastasis . Cancer Res 38:2651-2660, 1978 .

21.

Westerholm B. , Weichel B. , Eklund G. : Oral contraceptives, venous thromboembolic disease and ABO types.

22.

Lillie MA , Mink IB : Progestational agents and blood coagulation VI. Relationship of ABO types to changes induced by oral contraceptives. Am J Ostet Gynecol 119:406-410, 1972.

23.

Fagerhol M. , Abildgaard U. , Kornstad L. : Antithrombin-III concentration and ABO blood groups. Lancet i:664-665, 1971.

24.

Preston AE , Barr A. : The plasma concentration of factor VIII in the normal population. II. The effect of age, sex and blood group. Br J Haem 10:238-245, 1964.

25.

Opelz G. , Trasaki PL : Effect of blood-group on relation between HLA match and outcome of cadaver kidney transplants. Lancet i:220-222, 1977.

26.

Josy VC , Roger JH , Evans DB , et al: Differential between recipient ABO group and pretransplant blood transfusion. Transplantation 24:371-376, 1977.

27.

Bore PJ , Sells RA , Jameison V. , et al: Transfusion-induced renal allograft protection. Transplant Proc 11:148-151, 1979.

28.

Opelz G. , Mickey MR , Terasaki PI : Blood transfusion and kidney transplantation: Remaining controversies . Transplant Proc 13:136-141, 1981.

29.

Weiss DW : Tumor origin, progression, immunogenicity and immunotherapy. Transplant Proc 16:528-533, 1984.

30.

Horwich L. , Evans Dap , McConnell RB , et al: ABO blood groups in gastric bleeding. Gut 7:680-685, 1966.

31.

Atkinson JP , Frank MM : Interaction of complement cascade with coagulation, fibrinolytic and kinin generation systems. In: Clinical Immunology, Vol 1, ed. by Parker CW. Philadelphia, W.B. Saunders , 1980 , p 254.

32.

Ratnoff OD , Pensky J. , Ogton D. , et al: The inhibition of plasmin, plasma kallikrein, plasma permeability factor and C'Ir subcomponent of the first complement by serum C'I esterase inhibitor. J Exp Med 129:315-331, 1969.

33.

Kaplan AP : Trends in microvascular research. The Hageman factor-dependent pathways of human plasma. Microvasc Res 8:97-111, 1974.

34.

Goldsmith GH Jr , Saito H. , Ratnoff OD : The activation of plasminogen by Hageman factor (Factor XII) and Hageman factor fragment. J Clin Invest 62:54-60, 1978.

35.

Perlmutter DH , Colten HR : Molecular immunology of complement synthesis: A model of single cell control of effector-inhibitor balance. Ann Rev Immunol 4:231-251, 1986.

36.

Ukeless JC , Gordon S. , Reich R. : Secretion of plasminogen activator by stimulated macrophages. J Exp Med 139:834-850, 1974.

37.

Nubé MJ , Perijn MW , Kalf MW , et al: Kidney transplantation—transplant survival after planned HLA-A and -B matched blood transfusion. Tissue antigen 17:447-453, 1981.

38.

Nicolson GL , Custead SE : Tumor metastasis is not due to adaptation of cells to a new organ environment . Science 215:176-178, 1982.

39.

Cliffton EE , Agostino D. : The effect of fibrin formation and alterations in the clotting mechanism on the development of metastases. Vasc Dis 2:43-52, 1965.

40.

Gastpar H. : Stickiness of platelets and tumor cells influenced by drugs. Thromb Diath Hemorrh Suppl 42:291, 1970.

41.

Boeryd B. : Action of heparin and plasminogen inhibitor (EACA) on metastatic tumor spread in an isologous system. Acta Pathol Microbiol Scand 65:395-404, 1965.

42.

Cliffton EE , Agostino D. : Factor affecting the development of metastatic cancer. Effect of alteration in clotting mechanism. Cancer 15:276-283, 1962.

43.

Fisher B. , Fisher ER : Host factors influencing the development of metastases. Surg Clin North Am 42:335-351, 1962.

44.

Grossi CE , Agostino D. , Melamed M. , et al: Effect of human fibrinolysin on survival of carcinosarcoma 256 Walker cells in blood. Cancer 14:957-962, 1961.

45.

Johnson JH , Wood S. Jr: An in vivo study of fibrinolytic agents on V2 carcinoma cells and intravascular thrombi in rabbits. Bull Johns Hopkins Hosp 113:335-346, 1963.

46.

Cliffton EE , Agostino D. : Effect of inhibitors of fibrinolytic enzymes on development of pulmonary metastases. J Natl Cancer Inst 33:753-763, 1964.

47.

Salsbury AJ , White C. , Tsolakidid P. , et al: Fibrinolysis and circulating malignant cells. Surg Gynecol Obstet 136:733-736, 1973.

48.

Melone JM , Wangesteen SL , Moore WS , et al: The fibrinolytic system: A key to tumor metastasis. Ann Surg 190:342-349, 1979.

49.

Cliffton EE , Agostino D. : Cancer cells in blood in simulated colon cancer resectable and unresectable: Effect of fibrinolysis and heparin on growth potential. Surgery 50:395-401, 1961.